throbber
Br HeartJ7 1995;74:53-56
`
`53
`
`Concentration dependent cardiotoxicity of
`terodiline in patients treated for urinary
`incontinence
`
`Simon H L Thomas, P Daniel Higham, Kenneth Hartigan-Go, Farhad Kamali,
`Peter Wood, Ronald W F Campbell, Gary A Ford
`
`Abstract
`Objective-Terodiline, an antimuscarinic
`and calcium antagonist drug, was used to
`treat detrusor instability but was with-
`drawn in 1991 after provoking serious
`ventricular arrhythmias associated with
`increases in the corrected QT interval
`(QTc). This research was performed to
`relate drug induced electrocardiographic
`changes in asymptomatic recipients to
`plasma concentrations of the R( +) and
`S(-) terodiline enantiomers.
`Setting-Urological and geriatric clinics
`and wards.
`Subjects-Asymptomatic patients taking
`terodiline in stable dose.
`Methods-Electrocardiograms (50 mm/s)
`were collected from patients while they
`were taking terodiline and compared with
`ECGs obtained before or after terodiline.
`QT interval, heart rate corrected QT
`interval (QTc), and QT dispersion (QTd)
`were measured. Drug induced electro-
`cardiographic changes were related to
`plasma concentrations of R(+) and S(-)
`terodiline.
`Results-During
`terodiline
`treatment
`mean QTc and QTd were prolonged
`(491(43) and 84 (35) ms1l2) compared with
`measurements made off therapy (443 (33)
`and 42 (17) ms'12, paired t tests, P < 0-002
`and P < 0 01
`respectively)
`in the
`12
`patients in sinus rhythm. The mean (95%
`interval)
`confidence
`drug
`induced
`increases were 48 (23 to 74) Ms112 for QTc
`and 42 (13 to 70) ms'12 for QTd. These
`increases correlated with total plasma
`(QTc:
`terodiline
`r = 0-77, P < 0-006,
`QTd: r = 0*68, P < 0.025)
`and with
`plasma concentrations of both terodiline
`enantiomers.
`Conclusions-Terodiline increases QTc
`and QTd in a concentration dependent
`manner. It is not clear whether this is a
`stereoselective effect and, if so, which
`enantiomer is responsible. The results
`suggest that drug induced torsade de
`pointes is a type A (concentration depen-
`dent) adverse drug reaction.
`
`(Br HeartJ7 1995;74:53-56)
`
`Keywords: terodiline;
`graphy
`
`cardiotoxicity;
`
`electrocardio-
`
`Terodiline hydrochloride is an antimuscarinic
`drug with calcium antagonist
`properties'
`which was used for treating urinary inconti-
`nence caused by detrusor instability.2 The
`drug was withdrawn in 1991 after reports of
`cardiac dysrhythmia including bradycardia,
`heart block, ventricular fibrillation, and ven-
`tricular tachycardia, usually of the torsade de
`pointes-type34 and associated with QT pro-
`longation. Plasma terodiline concentrations
`were very high in one affected
`patient.
`Predisposing factors for terodiline associated
`torsade de pointes were old age, coexisting
`ischaemic heart disease, co-prescription of
`other cardioactive drugs, and hypokalaemia.
`Torsade de pointes is
`associated with
`abnormal prolongation of the ventricular
`refractory period which results in a long QT
`interval on the electrocardiogram and is often
`drug induced.5 Increased dispersion of ven-
`tricular recovery may be important in the
`development of this arrhythmia and indirect
`evidence indicates that this is reflected by
`increased dispersion of QT interval durations
`across the standard 12 lead electrocardio-
`gram.67 The relation between torsade de
`pointes and plasma drug concentrations is
`uncertain: while torsade may result from over-
`dose of several drugs,5 many patients develop-
`ing drug induced torsade do not have
`excessive plasma drug concentrations and
`some consider the arrhythmia to be an idio-
`synchratic phenomenon.8
`The effects of terodiline were therefore
`investigated by collecting electrocardiograms
`from asymptomatic patients receiving the
`drug for treatment of urinary incontinence,
`comparing them with those taken before or
`after drug treatment, and relating the terodi-
`line induced electrocardiographic
`changes
`with plasma concentrations of each terodiline
`enantiomer.
`
`Patients and methods
`Electrocardiograms (50 mm/s) and plasma
`samples were collected from patients who were
`taking terodiline in stable dose between 4 and
`24 h after the last dose. This process started
`in June 1991, when reports of dysrhythmia
`first appeared, and ended in September 1991
`when the drug was withdrawn. Copies of elec-
`trocardiograms predating terodiline treatment
`were also collected, when available, and, if
`possible, electrocardiography was repeated at
`
`Wolfson Dept of
`Clinical
`Pharmacology,
`University of
`Newcastle, Newcastle
`upon Tyne
`S H L Thomas
`K Hartigan-Go
`F Kamali
`P Wood
`G A Ford
`Academic
`Department of
`Cardiology,
`University of
`Newcastle, Newcastle
`upon Tyne
`P D Higham
`R W F Campbell
`Correspondence to:
`Dr S H L Thomas, Wolfson
`Department of Clinical
`Pharmacology, Claremont
`Place, Newcastle NE1 7RU.
`Accepted for publication
`11 January 1995
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1008 - Page 1
`
`

`
`54
`
`Thomas, Higham, Hartigan-Go, Kamali, Wood, Campbell, Ford
`
`100- /
`
`*
`
`.
`
`50
`
`*
`
`FO ioo0
`50
`
`0C
`
`0
`
`C'0
`R= 0.78, P < 0.005
`R 0.76, P<0.008
`u -50 -
`-50-
`0 100 200 300 400 500
`0 100 200 300 400 500
`150
`150
`100-
`100
`.C
`50
`50
`D
`CO0
`01
`-5 00. R 0-69, P < 002
`0 100 200 300 400 500
`R(+)-terodiline (ng/ml)
`
`.
`
`*.
`
`0
`
`R 0.67, P < 0.03
`0 100 200 300 400 500
`S(-)-terodiline (ng/ml)
`
`Characteristics ofpatients in sinus rhythm
`Table 1
`taking terodiline
`
`Mean (range)
`
`Age (years)
`Height (cm)
`Weight (kg)
`Daily dose (mg)*
`Duration of treatment (days)
`Sodium (mmol/l)
`Potassium (mmol/l)
`Creatinine (umol/l)
`Ionised calcium (mmol/l)
`Magnesium (mmolIl)
`Albumin (g/l)
`Values are mean (range). *Median daily dose was 25 mg.
`
`73 (46-92)
`161 (150-193)
`61 (44-90)
`38 (12-5-50)
`231 (8-1050)
`139 (136-142)
`4-1 (3 4-4 8)
`110 (89-116)
`1-30 (1-25-1-32)
`0-8 (0 7-0 9)
`41 (37-46)
`
`least 2 months after terodiline had been dis-
`continued. Each patient's medical details
`were recorded and the blood sample analysed
`for plasma drug concentrations, electrolytes,
`and creatinine.
`Electrocardiograms were analysed blind by
`an independent observer. RR, PR, and QT
`intervals were measured using a digitiser
`(Calcomp 9000, Scottsdale, AZ, USA). The
`QT interval was measured from onset of the
`QRS complex to the end of the T wave,
`defined as a return to the TP baseline. In the
`presence of U waves, the end of the T wave
`was taken at the TU nadir. Three representa-
`tive complexes were analysed for those leads
`of the standard 12 lead electrocardiogram
`where the T wave could be clearly defined
`and a mean taken. When the end of the T
`wave could not be reliably identified the lead
`was excluded from analysis. The largest QT
`interval on the 12 lead electrocardiogram
`(QTmax) was used to derive the corrected
`QT interval (QTc), which was calculated for
`each lead using Bazett's formula (QTc = QT/
`V (RR interval)). QT dispersion (QTd) was
`determined as the longest minus the shortest
`QTc on the 12 lead electrocardiogram.
`of R( + )-
`and
`concentrations
`Plasma
`S(-)- terodiline enantiomers were measured
`simultaneously by high performance liquid
`chromatography using a chiral column and an
`ultraviolet detector. The limit of detection of
`the method is 25 ng/ml for each enantiomer
`and coefficients of variation are 5-5% for the
`R(+)-enantiomer at 271 ng/ml and 7-6% for
`173 ng/ml.
`S(-)-enantiomer
`All
`the
`at
`samples were analysed in duplicate and with-
`out knowledge of the electrocardiographic
`changes observed in each patient.
`
`Results
`Nineteen patients taking terodiline took part
`in this study. The electrocardiograms of four
`
`Relation between plasma concentrations of
`Figure 2
`terodiline enantiomers and the extent of drug induced
`prolongation in corrected QT intervals (QTc) and QT
`dispersion (QTd).
`
`patients with atrial fibrillation were not used
`as this condition has major effects on QTd.
`For the 15 patients in sinus rhythm (table 1)
`before
`available
`electrocardiograms
`were
`terodiline was started in two patients and after
`terodiline had been stopped in 11, although
`one of these had developed atrial fibrillation.
`Electrocardiograms in sinus rhythm were
`therefore available during and before or after
`treatment in 12 patients, of whom 11 agreed
`to give a blood sample. Of these, one had
`right bundle branch block and four were taking
`other drugs which might affect QT interval
`(dothiepin, imipramine, thioridazine, sotalol),
`the doses of which were not altered during the
`study, and five had cardiovascular disease
`(three),
`disease
`(cerebrovascular
`coronary
`artery disease (one), and hypertension (one)).
`Electrocardiograms of two patients receiving
`terodiline were collected after only 8 and 16
`days of treatment, possibly before steady state
`concentrations and the maximal electrocar-
`diographic effects of the drug would be
`achieved.
`A total of 17 patients gave a blood sample.
`Plasma concentrations of the two terodiline
`closely
`(r = 0 99,
`correlated
`enantiomers
`P < 0 0001) with a mean (SD) R(+)-/S(-)-
`ratio of 1 03 (0 14). No significant correla-
`tions were observed between daily terodiline
`dose and the plasma concentration of either
`terodiline enantiomer. Apparent terodiline
`clearance, measured as daily dose divided by
`plasma concentration, varied widely between
`patients and did not correlate significantly
`with age in this small group (data not shown).
`Terodiline did not affect the PR interval or
`heart rate but prolonged QTc and QTd
`(fig 1, table 2) compared with measurements
`
`Table 2
`
`Electrocardiographic effect of terodiline in 12 patients in sinus rhythmn
`QTmax
`PR interval
`Heart rate
`(ms)
`(ms)
`(beatslmin)
`405 (49)
`166 (22)
`73 (16)
`456 (64)
`178 (26)
`72 (14)
`51
`12
`-2
`(17 to 85)
`(-3 to 26)
`(-10 to 7)
`NS
`NS
`P < 0 01
`
`Patients not receiving treatment
`Patients receiving treatment
`Mean difference
`(95% CI)
`Paired t test
`Values are mean (SD).
`
`QTc
`(msll2)
`443 (33)
`491 (43)
`48
`(23 to 74)
`P < 0-002
`
`QTd
`(ms)
`42 (17)
`84 (35)
`42
`(13 to 70)
`P < 0 01
`
`p < 0.002
`S
`
`I
`
`7
`
`{
`
`P < 0.01
`
`600_
`^550
`Ch 500 -
`Q450
`C) 400 -
`350 '
`
`150
`
`100
`
`50
`
`Off
`
`0 On
`Corrected QT
`Figure 1
`intervals (QTc) and QT
`dispersion (QTd) in 12
`patients in sinus rhythm on
`and off terodiline, together
`with means (SD). Four
`patients taking other drugs
`that prolong QTc are
`shown as crosses.
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1008 - Page 2
`
`

`
`Concentration dependent cardiotoxicity of terodiline in patients treatedfor urinary incontinence
`
`55
`
`made when patients were not receiving treat-
`ment. There was a
`positive
`correlation
`between absolute values of QTc and QTd in
`patients receiving terodiline
`(r = 0 70, P <
`0 005)
`terodiline
`and
`between
`induced
`increases in QTc and QTd (r = 0-88, P <
`0O001). Increases in QTmax, QTc, and QTd
`correlated significantly with the plasma con-
`centrations of terodiline and each of its enan-
`tiomers (fig 2).
`QTc was increased with terodiline in three
`patients whose electrocardiograms showed
`controlled atrial fibrillation on and off treat-
`ment. QTc was reduced with terodiline in one
`other patient, but this patient's atrial fibrilla-
`tion was uncontrolled (rate 11 0/min) when
`treatment was not given and the QTc is prob-
`ably invalid at this rate.
`
`Discussion
`The QT interval is an important factor in the
`genesis of ventricular arrhythmia. QTc pro-
`of 500 ms!"12 almost
`longation
`in
`excess
`inevitably accompanies torsade de pointes.9
`More modest prolongation is associated with
`an increased risk of sudden death in several
`patient groups.'1-2 Drugs that prolong the QT
`interval can cause ventricular arrhythmia and
`sudden death, for example, antiarrhythmic
`drugs, phenothiazines, and some antihista-
`mines.5 The risk of drug induced arrhythmia,
`however, is not determined by the QT interval
`alone; drugs with class III effects such as
`amiodarone increase QTc but are apparently
`associated with a low risk of torsade."3
`Furthermore,
`of
`evidence
`the
`relation
`between the risk of sudden death and the QTc
`interval in apparently healthy populations is
`conflicting. 14 15
`An important factor in the genesis of
`arrhythmia is the heterogeneity or dispersion
`of the duration of ventricular repolarisation.
`When dispersion is increased some areas of
`the ventricle will be refractory at times when
`others can allow unidirectional or bidirec-
`tional impulse propogation. This may estab-
`lish local re-entry circuits and ventricular
`tachycardia or fibrillation may then be trig-
`gered by critically placed ventricular prema-
`ture contractions.'6 Indirect evidence suggests
`that the interlead variability in QT interval
`durations obtained from the standard 12 lead
`electrocardiogram reflects increased disper-
`sion of ventricular recovery and the risk of
`arrhythmia67 1718 and sudden death.'9 QT
`necessarily
`dispersion
`does
`interval
`not
`increase as the QT interval lengthens: for
`example, amiodarone prolongs QTc without
`increasing QTd9 and this may explain its
`infrequent association with torsade. Early
`afterdepolarisations also seem to be important
`in the genesis of torsade and these might also
`be reflected in the 12 lead electrocardiogram
`as increased QTd.69 It is therefore important
`that QT interval and dispersion are measured
`when investigating the effects of drugs on ven-
`tricular repolarisation.
`Nine of the 10 patients described in the lit-
`erature who developed torsade de pointes
`
`while receiving terodiline had marked prolon-
`gation of the QTc interval,'3 4 20 however, daily
`terodiline doses were only a little higher
`(mean 40 mg) than in our asymptomatic
`group. Our results and those of a small open
`study of the effects of terodiline in elderly
`patients20 show that QTc prolongation is com-
`mon in asymptomatic patients receiving the
`drug, although this is less marked than in the
`patients with torsade de pointes. The observa-
`tion that terodiline also increases the disper-
`sion of ventricular recovery as measured by
`the QTd has not previously been reported.
`These effects correlate closely with plasma
`concentrations of the drug and its enan-
`tiomers confirming that this is a type A con-
`related
`centration
`adverse drug reaction,
`although some patients, for example, those
`with heart disease or hypokalaemia, may be
`particularly susceptible. Consistent with this,
`plasma terodiline concentration was sub-
`stantially higher (2946 ng/ml) in the one
`patient with torsade de pointes who had this
`measured4 than in our asymptomatic patients.
`Why some patients develop high concentra-
`tions of terodiline needs to be clarified. One
`risk factor is increasing age as elderly patients
`metabolise terodiline more slowly, with a
`mean elimination half life of 130-190 h2' 22
`compared with 63 h in younger patients.2'
`Thus it may take several weeks for steady state
`plasma concentrations to be achieved and
`these may be higher than anticipated. In addi-
`tion, there is considerable variability in the
`terodiline elimination half life between elderly
`individuals.2' 22 Variations in clearance proba-
`bly reflect differences in hepatic metabolism
`via p-hydroxyterodiline, the major route of
`elimination. This process may be affected by
`genetic polymorphism as clearance of R(+)-
`terodiline was reduced in a slow hydroxylator
`~~~~~24
`of
`of debrisoquine.4
`The terodiline enantiomers have stereose-
`lective actions. The R( + )-enantiomer is a
`more potent antimuscarinic agent,2526 while
`the S(-)-enantiomer has more marked cal-
`cium antagonist properties.25 In rats hydroxy-
`lation of the two enantiomers occurs at
`different rates, being more rapid for R(+)-
`terodiline.27 If this was also true in humans
`then it would be expected that plasma con-
`centrations of the S(-) enantiomer would be
`higher at steady state. In our patients, how-
`ever, plasma concentrations of each enan-
`therefore
`tiomer were similar, and it
`is
`unlikely that differential clearance occurs in
`humans. This is consistent with a previous
`observation that clearance of R( + )-terodiline
`is similar to that of the racemic drug.24
`This study does not indicate which of the
`enantiomers is most responsible
`for
`the
`observed electrophysiological effects, nor can
`it exclude the possibility that these are caused
`by a metabolite rather than the parent drug.
`Increases in QTc and QTd correlated signifi-
`cantly with both enantiomers, but the concen-
`trations of the enantiomers are closely related
`to each other. The most likely mechanism is
`potassium channel inhibition, a property of
`other QT prolonging drugs such as quinidine,
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1008 - Page 3
`
`

`
`56
`
`Thomas, Higham, Hartigan-Go, Kamali, Wood, Campbell, Ford
`
`amiodarone, and terfenadine.i28 To date the
`effects of terodiline enantiomers on cardiac
`potassium channels have not been studied.
`Important lessons from the terodiline expe-
`rience should be learned. It is clear from this
`and other data that if an effect of the drug on
`cardiac repolarisation had been sought during
`its development it would have been detected.
`This would have limited the use of the drug in
`high risk groups and resulted in closer moni-
`toring of patients while receiving therapy. In
`view of the close structural similarity to the
`proarrhythmic drug prenylamine,29 it is disap-
`pointing that electrocardiographic effects were
`not studied. Nevertheless it is reassuring that
`voluntary organised adverse drug reaction
`reporting by prescribers
`the
`United
`in
`Kingdom detected and characterised
`the
`problem.
`Studies using isolated detrusor muscle
`strips suggest that the beneficial effects of
`terodiline on the bladder are primarily medi-
`by the
`anticholinergic
`R( + )-enan-
`ated
`tiomer.26 If the adverse cardiovascular effects
`are caused by the S(-)-enantiomer then
`treatment with pure R( + )-terodiline might
`have an acceptable risk-benefit ratio. Studies
`to characterise further the electrophysiological
`effects of terodiline enantiomers in animals
`and humans would be useful.
`
`We are grateful to Kabi Pharmacia for supplies of racemic
`terodiline and its enantiomers, and to members of the urology
`department at the Freeman Hospital for their help with the
`study.
`
`1 Andersson K-E. Clinical pharmacology of terodiline.
`ScandJ7 Urol Nephrol 1984;87(suppl): 13-20
`2 Langtree HD, McTavish D. Terodiline: a review of its
`pharmacological properties and therapeutic use in the
`treatment of urinary incontinence.
`Drugs
`1990;40:
`748-61.
`3 McCloud AA, Thorogood S, Barnett S. Torsade de
`pointes complicating treatment with terodiline. BMJ
`1991;302: 1469.
`4 Connolly MJ, Astrige PS, White EG, Morley CA,
`Campbell Cowan J. Torsades de pointes ventricular
`tachycardia and terodiline. Lancet 1991;338:344-5.
`5 Thomas SHL. Drugs, QT interval prolongation and ven-
`tricular arrhythmias. Adv Drug React Tox Rev 1994;
`13:77-102.
`6 Higham PD, Campbell RWF. QT dispersion. Br Heart Jf
`1994;71:508-10.
`7 Day CP, McComb JM, Campbell RWF. QT dispersion:
`an indication of arrhythmia risk in patients with long QT
`intervals. Br HeartJ 1990;63:342-44.
`8 Zehender M, Hohnloser S, Just H. QT-interval prolonging
`drugs: mechanisms and clinical relevance of their
`Drugs &
`arrhythmogenic
`hazards.
`Cardiovascular
`Therapy 1991;5:515-30.
`
`9 Hii JTY, Wyse DG, Gillis AM, Duff HJ, Solyo MA,
`Mitchell LB. Precordial QT interval dispersion as a
`marker of torsade de pointes. Disparate effects of class
`la antiarrhythmic drugs and amiodarone. Circulation
`1992;86: 1376-82.
`10 Laakso M, Aberg A, Savola J, Pentikalinen PJ, Pyorala K.
`Diseases and drugs causing prolongation of the QT
`interval. AmJ Cardiol 1987;59:862-5.
`11 Algra A, Tijssen GP, Roeland RTC, Pool J, Lubsen J.
`QTc prolongation measured by standard 12 lead electro-
`cardiography is an independent risk factor for sudden
`death due to
`Circulation
`cardiac
`199 1;83:
`arrest.
`1888-94.
`12 Fioretti P, Tijssen GJP, Azar Lazzeroni E, et al. Prognostic
`significance of predischarge 12 lead electrocardiogram
`after myocardial infarction compared with other routine
`clinical variables. Br Heartr 1 987;57:306-12.
`13 Mattioni TA, Heutlin TA, Sarmiento JJ, Parker M, Lesch
`M, Kehoe RF. Amiodarone in patients with previous
`drug-mediated torsade de pointes: long term safety and
`efficacy. Ann Intern Med 1989;111:574-80.
`14 Goldberg RJ, Bengtson J, Chen Z, Anderson KM, Locati
`E, Levy D. Duration of the QT interval and total cardio-
`vascular mortality in healthy persons (the Framingham
`study experience). AmJ Cardiol 1991;67:55-8.
`15 Schoeten EG, Dekker JM, Meppelink P, Kok FJ,
`Vandenbroucke JP, Pool J. QT interval prolongation
`in an apparently
`predicts
`cardiovascular mortality
`healthy population. Circulation 199 1;84: 1516-23.
`16 Han J, Millet D, Chizzonette B, et al. Temporal dispersion
`of recovery of excitability in atrium and ventricle as a
`function of heart rate. Am HeartJ 1966;76:481-90.
`17 Day CP, McComb JM, Campbell RWF. QT dispersion in
`sinus beats and ventricular extrasystoles in normal
`hearts. Br HeartJ 1992;67:266-8.
`18 Day CP, McComb JM, Mathews J, Campbell RWF.
`following
`Reduction in QT dispersion by sotalol
`myocardial infarction. EurHeartJr 1991;12:423-7.
`19 Barr CS, Naas A, Freeman N, Lang CC, Struthers AD.
`QT dispersion and sudden unexplained death in chronic
`heart failure. Lancet 1994;343:327-9.
`20 Stewart DA, Taylor J, Ghosh S, et al. Terodiline causes
`polymorphic ventricular tachycardia due to reduced
`heart rate and prolongation of QT interval. Eur J Clin
`Pharmacol 1992;42:577-80.
`21 Hallen B, Magnusson A, Bogentoft S, Ekelund P. Single-
`and multiple-dose pharmacokinetics of terodiline in geri-
`atric patients. EurJ Clin Pharmacol 1988;34:291-7.
`22 Hallen B, Bogentoft S, Sandquist S, Stromberg S,
`Setterberg G, Ryd-Kjelen E. Tolerability and steady
`state pharmacokinetics of terodiline and its main
`metabolites in elderly patients with urinary incontinence.
`EurJ7 Clin Pharmacol 1989;36:487-93.
`23 Karlen B, Andersson K-E, Ekman G, Stromberg S,
`Ulmsten U. Pharmacokinetics of terodiline in human
`volunteers. EurJ7 Clin Pharmacol 1982;23:267-70.
`24 Hallen
`B,
`Palmer J,
`Gabrielsson
`Ekstrom B.
`B,
`of R-( + )-terodiline
`given
`intra-
`Pharmacokinetics
`venously and orally to healthy volunteers. Pharmacol
`Toxicol 1993;73:153-8.
`25 Larsson-Backstrom C, Arrenius E, Sagge K. Comparison
`of the calcium-antagonistic effects of terodiline, nifedipine
`and verapamil. Acta Pharmacologica & Toxicologica 1985;
`57:8-17.
`26 Andersson K-E, Ekstrom B, Mattiasson A. Actions of
`terodiline, its isomers and main metabolite on isolated
`detrusor muscle from rabbit and man. Acta Pharmacol &
`Toxicol 1988-63:390-5.
`27 Lindeke B, Ericsson 0, Jonsson A, Noren B, Stromberg S,
`Vangbo B.
`terodiline.
`of
`III.
`Biotransformations
`Opposed stereoselectivity in the benzylic and aromatic
`liver microsomes. Xenobiotica
`hydroxylations
`in
`rat
`1987;17: 1269-78.
`28 Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of
`the cardiotoxic actions of terfenadine. _AMA 1993;269:
`1532-6.
`29 Puritz R, Henderson MA, Baker SN, Chamberlain DA.
`Ventricular arrhythmias caused by prenylamine. BM3
`1977;2:608-9.
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1008 - Page 4

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket